09.10.15
Sorin SpA and Cyberonics Inc. have appointed the new chief financial officer for the new company forming from their merger, LivaNova. Vivid Sehgal will take his position at the close of the merger, and will report directly to André-Michel Ballester. Ballester is CEO of Sorin and will assume the same position for LivaNova. Sehgal will be based in the new company’s headquarters in London, United Kingdom.
Sehgal brings more than 25 years of financial, operational and compliance leadership, most recently with Allergan Inc., where he served as senior vice president, treasury, risk & investor relations. There, he played a lead role in the company’s capital deployment and risk strategies, culminating in the $66 billion sale of Allergan to Actavis plc.
Previously, Sehgal served as vice president and regional controller of Allergan’s Europe, Middle East and Africa (EMEA) business, where he was responsible for finance, accounting, information technology, market research, data quality and sales operations covering more than 60 countries. He played a key role in the formulation and execution of the group’s strategy for international acquisitions and expansion into key emerging markets.
Prior to Allergan, Sehgal worked in various roles with GlaxoSmithKline and SmithKline Beecham for nine years, with his last position being group controller for the International Pharmaceutical Division, with sales of more than $13 billion. He brings additional financial leadership experience from other companies, including the Gillette Company during its acquisition by Procter & Gamble Inc. and Grand Metropolitan plc.
Sehgal earned his master’s degree in finance and investment from the University of Exeter and a bachelor’s degree in economics from the University of Leicester, both in England. He is a member of the Chartered Institute of Management Accountants.
“Vivid brings a wide variety of experience to LivaNova, including the development of shared services, strategic planning, Sarbanes-Oxley implementation and merger integration,” commented Ballester. “We are delighted to welcome Vivid as a key member of our senior management team.”
Greg Browne, interim chief financial officer of LivaNova, will continue to support LivaNova in a transitional capacity until, as previously announced, his retirement in mid-year of 2016.
Sehgal brings more than 25 years of financial, operational and compliance leadership, most recently with Allergan Inc., where he served as senior vice president, treasury, risk & investor relations. There, he played a lead role in the company’s capital deployment and risk strategies, culminating in the $66 billion sale of Allergan to Actavis plc.
Previously, Sehgal served as vice president and regional controller of Allergan’s Europe, Middle East and Africa (EMEA) business, where he was responsible for finance, accounting, information technology, market research, data quality and sales operations covering more than 60 countries. He played a key role in the formulation and execution of the group’s strategy for international acquisitions and expansion into key emerging markets.
Prior to Allergan, Sehgal worked in various roles with GlaxoSmithKline and SmithKline Beecham for nine years, with his last position being group controller for the International Pharmaceutical Division, with sales of more than $13 billion. He brings additional financial leadership experience from other companies, including the Gillette Company during its acquisition by Procter & Gamble Inc. and Grand Metropolitan plc.
Sehgal earned his master’s degree in finance and investment from the University of Exeter and a bachelor’s degree in economics from the University of Leicester, both in England. He is a member of the Chartered Institute of Management Accountants.
“Vivid brings a wide variety of experience to LivaNova, including the development of shared services, strategic planning, Sarbanes-Oxley implementation and merger integration,” commented Ballester. “We are delighted to welcome Vivid as a key member of our senior management team.”
Greg Browne, interim chief financial officer of LivaNova, will continue to support LivaNova in a transitional capacity until, as previously announced, his retirement in mid-year of 2016.